Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

What happened

Boston Scientific reported third-quarter revenue up 1.5% from a year earlier, beating analyst estimates, with adjusted earnings per share of $0.73 also above expectations. The company said an August 2026 cybersecurity incident affected operations and customer support during the quarter.

Confirmed

Global impact / market context

The beat shows the medical device maker sold more than expected despite a cybersecurity incident that disrupted operations and customer support. But management's own forecast for fourth-quarter sales to fall shows the damage may weigh on revenue and costs beyond the quarter just reported.

Analyst inference

Analysts rate the shares a buy on average, with no sell ratings, so expectations are positive. A forecast of falling fourth-quarter sales and slower full-year growth could push investors to reassess how much of the beat came from underlying demand versus timing of orders.

Analyst inference

What to watch

1. Boston Scientific forecasts fourth-quarter net sales to decline year-on-year, with adjusted earnings per share expected at $0.77 to $0.79. Watch whether the company links that decline to the cybersecurity incident. Confirmed
2. Watch whether Boston Scientific restores affected operations and customer support, and whether it discloses costs tied to the August 2026 cybersecurity incident, since added costs would reduce profit even if sales recover. Proposed
3. Watch the Urology segment, which fell 3.2%, and U.S. sales, up only 0.5%, for signs that weak demand, not just the cyber incident, is weighing on growth as the company enters the fourth quarter. Analyst inference

Evidence

• Original source link unavailable